苑东生物 (688513)

1. Key Indicators

• Total Shares(W): 17653.23
• Circulating A-Shares(W): 17653.23
• Earnings Per Share(RMB): 1.2500
• Net Assets Per Share(RMB): 16.2349
• Operating Revenue(W RMB): 101913.36
• Total Profit(W RMB): 24208.98
• **Net Profit Attributable to Parent(W RMB) **: 22016.25
• Net Profit Growth Rate(%): 1.45
• Weighted Return on Equity(%): 7.9300
• Operating Cash Flow Per Share(RMB): 1.2400
• Undistributed Profit Per Share(RMB): 7.2264
• Capital Reserve Per Share(RMB): 7.9293

---

2. Main Business

The main business covers:

• Research, production, and sales of chemical raw materials and chemical drug preparations

---

3. Company Basic Information

• Company Name: Chengdu Easton Biopharmaceuticals Co., Ltd.
• Listing Date: 2020-09-02
• Industry: Pharmaceutical Manufacturing
• Address: No. 8 Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province
• Website: https://www.eastonpharma.cn
• Company Profile: The company was established by converting Easton Co., Ltd. into a joint stock company. In December 2015, Zhonghui Accounting Firm was commissioned to audit the net assets of Easton Co., Ltd. as of the base date of September 30, 2015, and issued an audit report. The audited net asset value of Easton Co., Ltd. as of September 30, 2015, was RMB 220.2926 million. In December 2015, Tianyuan Asset Appraisal Co., Ltd. was commissioned to appraise the net assets of Easton Co., Ltd. as of the base date of September 30, 2015, and issued an asset appraisal report. The appraised net asset value of Easton Co., Ltd. as of September 30, 2015, was RMB 273.2308 million. In December 2015, Easton Co., Ltd. held a shareholders' meeting, which reviewed and unanimously passed a resolution to legally convert Easton Co., Ltd. into a joint stock company with the 15 shareholders of Easton Co., Ltd. as joint promoters, based on the date of September 30, 2015. The registered capital of Easton Biopharmaceuticals was based on the audited net asset value of Easton Co., Ltd. of RMB 220.2926 million as of September 30, 2015, converted into 86.5 million shares of Easton Biopharmaceuticals, with a par value of RMB 1.00 per share. After the conversion, the registered capital (total share capital) of Easton Biopharmaceuticals was RMB 86.5 million, and the balance of the net assets after deducting the share capital, RMB 133.7926 million, was included in the capital reserve. The above conversion matters were verified by Zhonghui Accounting Firm. In December 2015, Easton Biopharmaceuticals completed the industrial and commercial change registration procedures for the above matters.

---

4. Top 10 Circulating Shareholders

Rank	Institution Name	Institution Type	Shares Held (W)	Percentage Held (%)
1	Chengdu Nanyuan Investment Partnership (Limited Partnership)	General Legal Person	512.95	2.91
2	Guotai Jiatai Stock Special Pension Product - China Merchants Bank Co., Ltd.	Asset Management Plan	220.37	1.25
3	Bosera Research Preferred Flexible Allocation Hybrid Securities Investment Fund (LOF) Class A	Fund	163.51	0.93
4	Great Wall Pharmaceutical Industry Selected Hybrid Initiation Securities Investment Fund Class A	Fund	162.21	0.92
5	Industrial Health Care Hybrid Securities Investment Fund Class A	Fund	48.18	0.27
6	Bosera Value Selection Two-Year Holding Period Flexible Allocation Hybrid Securities Investment Fund Class A	Fund	34.14	0.19
7	Puyin Ansheng Value Growth Hybrid Securities Investment Fund Class A	Fund	30.21	0.17
8	Puyin Ansheng Health Care Flexible Allocation Hybrid Securities Investment Fund Class A	Fund	26.48	0.15
9	Hongtu Innovation Health Care Stock Initiation Securities Investment Fund	Fund	23.83	0.13
10	Bosera Growth Preferred Flexible Allocation Hybrid Securities Investment Fund Class A	Fund	23.58	0.13

---

5. Concept Sectors

• Generic Drugs
• Innovative Drugs
• Margin Trading & Securities Lending
• High-Performance Stocks
• Science and Technology Innovation Board Biotech
• Science and Technology Innovation 200
• SSE 580

---

Remarks

• Data update date: 2025-11-10
• Data source: Public market information